menu search

elevar therapeutics announces publication of phase 3 cares 310 study results in the lancet

In CARES 310, camrelizumab plus rivoceranib demonstrated statistically significant and clinically meaningful prolonged overall survival and progressio...

July 25, 2023, 1:39 am


Search within

Pages Search Results: